Cargando…

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway

Mostrar otras versiones (1)

Castration-resistant prostate cancer (CRPC) is a major challenge in the treatment of prostate cancer (PCa). Phospholipase Cε (PLCε), an oncogene, has been found to be involved in the carcinogenesis, tumor proliferation and migration of several types of cancer. The effects, however, of PLCε on CRPC r...

Descripción completa

Detalles Bibliográficos
Autores principales:	Sun, Wei, Li, Luo, Du, Zhongbo, Quan, Zhen, Yuan, Mengjuan, Cheng, Honglin, Gao, Yingying, Luo, Chunli, Wu, Xiaohou
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	D.A. Spandidos 2019
Materias:	Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6448124/ https://www.ncbi.nlm.nih.gov/pubmed/30864728 http://dx.doi.org/10.3892/or.2019.7054

Ejemplares similares

Combination of phospholipase Cε knockdown with GANT61 sensitizes castration-resistant prostate cancer cells to enzalutamide by suppressing the androgen receptor signaling pathway
por: Sun, Wei, et al.
Publicado: (2022)

Phospholipase C (PLC)ɛ Promotes Androgen Receptor Antagonist Resistance via the Bone Morphogenetic Protein (BMP)-6/SMAD Axis in a Castration-Resistant Prostate Cancer Cell Line
por: Yuan, Mengjuan, et al.
Publicado: (2019)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2020)

PLCε knockdown enhances the radiosensitivity of castration-resistant prostate cancer via the AR/PARP1/DNA-PKcs axis
por: Pu, Jun, et al.
Publicado: (2022)

Simvastatin delays castration-resistant prostate cancer metastasis and androgen receptor antagonist resistance by regulating the expression of caveolin-1
por: Gao, Yingying, et al.
Publicado: (2019)

Inhibitor 9 Combined With Androgen Deprivation Therapy or Chemotherapy Delays the Malignant Behavior of Castration-Resistant Prostate Cancer Through K-Ras/PLCε/PKCε Signaling Pathway
por: Liu, Jiayu, et al.
Publicado: (2020)

Systematic Evaluation for the Influences of the SOX17/Notch Receptor Family Members on Reversing Enzalutamide Resistance in Castration-Resistant Prostate Cancer Cells
por: Du, Zhongbo, et al.
Publicado: (2021)

HepaCAM inhibits the malignant behavior of castration-resistant prostate cancer cells by downregulating Notch signaling and PF-3084014 (a γ-secretase inhibitor) partly reverses the resistance of refractory prostate cancer to docetaxel and enzalutamide in vitro
por: Du, Zhongbo, et al.
Publicado: (2018)

PLCε promotes urinary bladder cancer cells proliferation through STAT3/LDHA pathway-mediated glycolysis
por: Cheng, Honglin, et al.
Publicado: (2019)

Knockdown of Phospholipase Cɛ (PLCɛ) Inhibits Cell Proliferation via Phosphatase and Tensin Homolog Deleted on Chromosome 10 (PTEN)/AKT Signaling Pathway in Human Prostate Cancer
por: Wang, Xiao, et al.
Publicado: (2018)

SOX8 Knockdown Overcomes Enzalutamide Resistance in Castration-Resistant Prostate Cancer by Inhibiting the Notch Signaling Pathway
por: Du, Zhongbo, et al.
Publicado: (2022)

HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain
por: Deng, Qingfu, et al.
Publicado: (2019)

HepaCAM inhibits cell proliferation and invasion in prostate cancer by suppressing nuclear translocation of the androgen receptor via its cytoplasmic domain
por: Deng, Qingfu, et al.
Publicado: (2022)

The Effect of Metformin and GANT61 Combinations on the Radiosensitivity of Prostate Cancer Cells
por: Gonnissen, Annelies, et al.
Publicado: (2017)

Enzalutamide: targeting the androgen signalling pathway in metastatic castration‐resistant prostate cancer
por: Schalken, Jack, et al.
Publicado: (2015)

Acquired resistance to the second-generation androgen receptor antagonist enzalutamide in castration-resistant prostate cancer
por: Kregel, Steven, et al.
Publicado: (2016)

GANT61, a GLI inhibitor, sensitizes glioma cells to the temozolomide treatment
por: Li, Jianlong, et al.
Publicado: (2016)

Unraveling the therapeutic potential of GANT61/Dactolisib combination as a novel prostate cancer modality
por: Youssef, Mohamed, et al.
Publicado: (2022)

PLCε regulates prostate cancer mitochondrial oxidative metabolism and migration via upregulation of Twist1
por: Fan, Jiaxin, et al.
Publicado: (2019)

Phospholipase Cɛ Regulates Prostate Cancer Lipid Metabolism and Proliferation by Targeting AMP-Activated Protein Kinase (AMPK)/Sterol Regulatory Element-Binding Protein 1 (SREBP-1) Signaling Pathway
por: Zheng, Yongbo, et al.
Publicado: (2020)

The protective autophagy activated by GANT-61 in MYCN amplified neuroblastoma cells is mediated by PERK
por: Wang, Jing, et al.
Publicado: (2018)

Chemical, computational and functional insights into the chemical stability of the Hedgehog pathway inhibitor GANT61
por: Calcaterra, Andrea, et al.
Publicado: (2018)

GANT61/BI-847325 combination: a new hope in lung cancer treatment
por: El-Kishky, Abdel Halim M., et al.
Publicado: (2022)

The hedgehog inhibitor GANT61 sensitizes prostate cancer cells to ionizing radiation both in vitro and in vivo
por: Gonnissen, Annelies, et al.
Publicado: (2016)

Enzalutamide for patients with metastatic castration-resistant prostate cancer
por: Ramadan, Wijdan H, et al.
Publicado: (2015)

Enzalutamide for the treatment of metastatic castration-resistant prostate cancer
por: Rodriguez-Vida, Alejo, et al.
Publicado: (2015)

Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer
por: Luo, Mayao, et al.
Publicado: (2022)

Inhibition of autophagy potentiates the efficacy of Gli inhibitor GANT-61 in MYCN-amplified neuroblastoma cells
por: Wang, Jing, et al.
Publicado: (2014)

Mitochondria-derived reactive oxygen species drive GANT61-induced mesothelioma cell apoptosis
por: Lim, Chuan Bian, et al.
Publicado: (2015)

Targeting GLI by GANT61 involves mechanisms dependent on inhibition of both transcription and DNA licensing
por: Zhang, Ruowen, et al.
Publicado: (2016)

Alterations of androgen receptor-regulated enhancer RNAs (eRNAs) contribute to enzalutamide resistance in castration-resistant prostate cancer
por: Zhao, Jingwen, et al.
Publicado: (2016)

Long noncoding RNA HOTAIR regulates the invasion and metastasis of prostate cancer by targeting hepaCAM
por: Li, Ting, et al.
Publicado: (2020)

The MAO inhibitors phenelzine and clorgyline revert enzalutamide resistance in castration resistant prostate cancer
por: Wang, Keliang, et al.
Publicado: (2020)

Impact of enzalutamide on patient-related outcomes in metastatic castration-resistant prostate cancer: current perspectives
por: Luo, Jia, et al.
Publicado: (2016)

Metastatic Castration-Resistant Prostate Cancer: Critical Review of Enzalutamide
por: El-Amm, Joelle, et al.
Publicado: (2013)

Enzalutamide-resistant castration-resistant prostate cancer: challenges and solutions
por: Tucci, Marcello, et al.
Publicado: (2018)

Budget Impact of Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer
por: Schultz, Neil M., et al.
Publicado: (2020)

Mode and specificity of binding of the small molecule GANT61 to GLI determines inhibition of GLI-DNA binding
por: Agyeman, Akwasi, et al.
Publicado: (2014)

Miss Zilphia Gant
por: Faulkner, William, 1897-1962
Publicado: (1971)

Miss Zilphia Gant
por: Faulkner, William, 1897-1962

Cannot write session to /tmp/vufind_sessions/sess_70lffv843m1tv1s56fk7e5iukg